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ABSTRACT
Since its first introduction in clinical practice in 2008, 
the concept of mobile stroke unit enabling prehospital 
stroke treatment has rapidly expanded worldwide. This 
review summarises current knowledge in this young field 
of stroke research, discussing topics such as benefits in 
reduction of delay before treatment, vascular imaging- 
based triage of patients with large- vessel occlusion in 
the field, differential blood pressure management or 
prehospital antagonisation of anticoagulants. However, 
before mobile stroke units can become routine, several 
questions remain to be answered. Current research, 
therefore, focuses on safety, long- term medical benefit, 
best setting and cost- efficiency as crucial determinants 
for the sustainability of this novel strategy of acute stroke 
management.
BACKGROUND
Stroke is an important cause of mortality and 
disability, with severe medical and economic conse-
quences.1 Efficient causal treatments for acute 
stroke are thrombolysis2 and intra- arterial therapy 
(IAT),3 however, both are extremely time- sensitive. 
Many studies showed improved outcomes when 
delays before treatment were reduced. For example, 
in the Highly Effective Reperfusion Evaluated in 
Multiple Endovascular Stroke trial, 10 min earlier 
thrombectomy estimated to gain 39 disability- free 
days.4
In addition to decreasing the effectiveness of 
recanalising strategies, delays also preclude many 
patients from receiving such treatment at all. 
This fact is reflected in the low reported rates of 
treatment: in US registries, approximately 10% of 
patients who had an acute ischaemic stroke were 
treated with thrombolysis and approximately 2% 
with IAT.5 6 The main reasons for treatment delays 
are related to arriving too late in the hospital for 
treatment, indicating the urgency for reconfigura-
tion of current systems of care.7
This review focuses on current advances in 
prehospital stroke treatment and the recently devel-
oped mobile stroke units (MSUs) aimed at enabling 
a timely delivery of acute stroke treatment.
Search strategy and selection criteria
We searched the PubMed database for articles 
containing the term stroke in combination with 
prehospital or Mobile Stroke Unit and published 
between 1 January 2015 and 31 December 2020. 
The search yielded 787 published articles. We 
examined these articles with a focus on originality, 
timeliness and relevance to the scope of this review.
The MSU concept: ‘bringing the hospital to the 
patient’
At present, acute stroke management guide-
lines recommend that, after first assessment and 
stabilisation, patients who had a stroke should 
rapidly be transported to the nearest stroke- ready 
hospital for diagnostic work- up and acute treat-
ment.8 9 However, effective treatments are now 
available that could, in principle, be adminis-
tered directly at the emergency site. Therefore, in 
contrast to the current practice of awaiting patients 
to arrive at the hospital before diagnosis and treat-
ment can begin, a scientific concept for the delivery 
of stroke treatment directly at the emergency site 
was first published in 200310 and was first intro-
duced in clinical practice in 2008.11 12 This concept 
was made possible by the implementation of all 
required equipment for diagnosis and treatment in 
an ambulance, including CT, point- of- care (POC) 
laboratory, telemedicine connection to hospitals 
and advanced stroke medications.
Apart from a reduction in treatment delays by 
cutting transport times and reducing the number of 
crucial interfaces between groups of various health-
care professionals, an equally important advantage 
of MSUs is the option of diagnosis- based triage 
decision- making with regard to transport to the 
individually required target hospital. The MSU, 
acting synergistically with hospital- based stroke 
units, was aimed to extend specialised stroke care 
to the prehospital phase of stroke management.10
Technical aspects
MSU ambulance
The ambulance, the basis of the MSU, varies world-
wide with regard to dimensions according to the 
specific needs of the various regions and health-
care systems. Some MSUs focus on small and light-
weight standard solutions, thereby reducing costs, 
facilitating speed, allowing access to narrow roads 
and increasing acceptance by Emergency Medical 
Services (EMS) healthcare professionals, who find 
their familiar working environment. However, 
larger vehicles may be advantageous in other specific 
settings. For example, providing extra space allows 
relatives to accompany the patient in the MSU to 
provide history and informed consent for later 
medical procedures. They may also incorporate 
larger scanners, and their more robust construction 
allows coping with challenging street conditions.
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Imaging
Imaging is the cornerstone of acute stroke treatment. It provides 
the answers to two key questions: (1) whether the patient is 
a candidate for tissue plasminogen activator (tPA), that is, by 
exclusion of intracranial haemorrhage, and (2) whether the 
patient should undergo IAT in a comprehensive stroke centre 
(CSC) because of large- vessel occlusion (LVO). For that reason, 
cerebral imaging is a main component of the MSU concept.
Although mobile CT scanners dedicated to head imaging and 
constructed for use in intensive care units and with acceptable 
resolution (eg, Tomoscan M, Philips, The Netherlands) have 
been available since the 1990s, they were first placed into an 
ambulance for prehospital stroke care in 2008.11 A common 
disadvantage of all mobile head scanners is their inability to scan 
below the C2 vertebra; such a capability could be relevant for 
assessing obstructions of proximal neck vessels. However, at 
present, there is no clear evidence for recanalisation of prox-
imal carotid or vertebral artery occlusions, and no guidelines 
currently recommend this procedure. One project, carried out 
in Memphis, Tennessee, USA, uses a whole- body scanner that 
not only allows scanning of the proximal brain- supplying vessels 
but also provides higher resolution, although at the expense of a 
larger size and more weight.13
Whereas unenhanced imaging can already exclude haem-
orrhage, multimodal imaging, including vascular (CT angi-
ography) and perfusion (CT perfusion) imaging, is crucial for 
identifying LVO and the tissue at risk. CT angiography in the 
field has been shown to allow rapid detection of LVO, a precon-
dition for correct decision- making for or against transfer to a 
thrombectomy- capable stroke centre14–17 (figure 1A,B).
Automated imaging assessment software
The presence of early infarct signs indicating that ischaemic 
injury has existed already for some hours is an important 
predictor of poorer response to thrombolysis and of a higher 
rate of worse events.18 As a solution to the problem of high 
inter- rater variability in detecting those signs, the Alberta Stroke 
Program Early CT Score (ASPECTS) was developed to provide 
a standardised topographic system for scoring CT scans in acute 
stroke management.
Because determination of ASPECTS requires substantial 
experience, automated image analysis tools have been devel-
oped more recently.19 During MSU missions, such software can 
support decision- making for or against thrombolysis in the field, 
as previously shown.20 Apart from ischaemic brain damage, 
they may also allow detection of LVO, even on non- contrast CT 
scans, thereby potentially contributing to improve prehospital 
triage decision- making.21
Prehospital POC laboratory
MSUs contain a complex POC laboratory for performing labora-
tory tests in the field. Quantification of haematological, clinical 
chemistry and coagulation markers can be obtained with small, 
commercially available portable laboratory devices. Before such 
equipment was implemented in the MSU, a study showed that 
the results of POC testing indeed agreed with those of analyses 
in centralised hospital laboratories.22 The POC laboratory plat-
form can also quantify renal function markers, which are rele-
vant for the performance of CT angiography.16 To the best of 
our knowledge, only the first randomised trial in Homburg, 
Germany, performed between 2008 and 2011, placed the same 
set of POC laboratory devices found in the MSU also in the 
hospital; this similarity served to improve the comparability of 
the study groups.14
Telecommunication between MSU and hospital
Telecommunication between the MSU and the hospital is a crucial 
component of the MSU.23 Telemedical interaction includes real- 
time bidirectional audio–video communication and exchange of 
videos, CT scans and other potentially relevant information.10 
Telemedicine connection enables the MSU team to obtain valu-
able guidance from hospital experts.10 11
Commercially available telestroke systems have been refined 
over time and now allow the transmission of imaging and 
communication data into the picture archiving and communica-
tion system of the hospital.11 After initial problems with connec-
tivity, important improvements in the reliability of telestroke 
systems have been reported with the establishment of 4G 
networks. Studies have shown that telemedical assessments were 
successful for 99 of 100 patients (99%)24 and achieved a success 
rate of 100% for 11 treated patients.25 A study involving 174 
patients compared assessment by a vascular neurologist aboard 
the MSU and a remote telemedicine- based vascular neurolo-
gist. The comparison found 98% satisfactory connectivity and 
88% agreement in the decision for or against the administra-
tion of tPA.26 A study by Bowry et al,27 involving 50 consecu-
tively assessed patients, found that telemedical consultation of a 
vascular specialist achieved a level of accuracy for neurological 
assessment that was comparable with the accuracy achieved by 
an on- board vascular neurologist, without causing treatment 
Figure 1 Prehospital unenhanced CT scans (A) and CT angiography 
images (B) of a patient who had an acute stroke caused by large- 
vessel occlusion of the left middle cerebral artery (arrow), enabling a 
triage decision to transport a patient to a CSC for intra- arterial therapy. 
Prehospital unenhanced CT scanning (C) and CT angiography images 
(D) of a patient with a hypertensive intracerebral haemorrhage in the 
basal ganglia with a ‘spot sign’ (arrow), indicating ongoing bleeding and 
enabling a triage decision to transport to a CSC for neurointensive care. 
CSC, comprehensive stroke centre.
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delays. Finally, some studies have described in detail the inte-
gration of data generated aboard the MSU into a hospital’s elec-
tronic health records.28 29
Staffing and dispatch of MSUs
Because a 100% reliable connection could not be achieved in the 
initial phase of MSU research, a vascular neurologist trained in 
the administration of radiation or even a neuroradiologist had to 
be part of the MSU personnel for compliance with regional regu-
lations. As connectivity improved, it became possible to rely on 
paramedics, nurses and technicians who were guided remotely 
by hospital experts via telemedicine.24 However, most projects 
are still based on the presence of vascular physicians in the MSU.
Because current legal restrictions usually lag behind novel 
developments, most MSU projects act ‘on top’ to rather than 
replacing the conventional EMS in response to acute stroke. 
In some settings, however, MSUs with a vascular physician 
on- board act alone when the EMS code ‘stroke’ is activated.30 
In Norway, MSUs are staffed with anaesthesiologists, trained 
in stroke medicine.31 32 In general, modalities of interaction 
between MSU and regular EMS strongly depend on the regional 
EMS system’s rules, conventions and resources, which are highly 
divergent.17
Team approach and efficiency at intersections
Whereas in the hospital various members of the stroke rescue 
chain are subsequently activated and interact, separated by 
different locations, the MSU staff works at one site, on one 
patient, and at the same time, in a parallel workflow manner. The 
fact that treatment in an MSU holds, so far, the ‘world record’ 
in time to treatment14 can, apart from reduction of transport 
times, be explained by such highly structured team approach and 
the considerable reduction of intersections between the various 
groups of healthcare professionals.
Interaction between EMS and MSU
More in general, to prevent delays and restrict or even completely 
prevent implementation of an MSU, agreements for cooper-
ation with stakeholders of healthcare systems with competing 
interests must be settled early in the planning stage of the MSU 
programme. The legal and procedural obstacles obviously differ 
widely according to region, healthcare political framework and 
EMS configuration.
The mode of interaction between a conventional EMS 
ambulance and MSU is rather heterogeneous in the current 
programmes. Although nearly all MSU projects act in addition 
to conventional EMS, an MSU at Southend, UK acts alone.30 
Although in most projects (USA, Europe) the MSU is dispatched 
in parallel to the regular EMS, the MSU can, in addition, also 
be activated in a tiered manner by the first responding EMS on 
scene (eg, Houston, Texas, USA). Finally, in some locations the 
MSU can also be directly activated by the patients or relatives in 
case of stroke (Bangkok, Thailand).
Identification of stroke during the telephone call from patients 
or bystanders is a challenge for EMS dispatchers; their reported 
success rates range from 30% to 83%.17 33 For the dispatch of 
MSUs, the correct identification of stroke symptoms is crucial. 
On the one hand, sensitivity must be as high as possible so that 
strokes are not missed; on the other hand, specificity must also 
be good so that the number of MSU dispatches to patients who 
had stroke mimics remains as low as possible. In many regions, 
Figure 2 Gains in time from emergency call (left) or symptom onset (right) to treatment or treatment decision conferred by use of mobile stroke units 
(MSUs) in comparison with standard treatment in various controlled studies. The referring studies were published by (1) Taqui et al,40 (2) Ebinger et al,38 (3) 
Walter et al,14 (4) Shownkeen et al,55 (5) Kummer et al,56 (6) Grotta et al57 and (7) Ebinger et al.58 tPA, tissue plasminogen activator.
Figure 3 Rates of therapy decisions for or against thrombolysis (end of 
all required diagnostic work- up, including laboratory and imaging studies) 
during the golden hour for patients treated in a mobile stroke unit (MSU) 
and those given standard treatment in the first randomised trial.14
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stroke recognition in the dispatch office is based on standard 
questions that are in turn based on stroke scales, such as the 
Face, Arm, Speech, Time (FAST) Scale, the extended FAST 
Scale,34 the Dispatcher Identification Algorithm for Stroke 
Emergencies Scale35 or the Recognition of Stroke in the Emer-
gency Room Scale,14 36 although to date, none of the scales 




The first randomised trial performed in Homburg, Germany, 
between 2008 and 2011, found that MSU- based stroke manage-
ment significantly reduces times to treatment.14 Symptom onset- 
to- treatment time was 72 min (IQR: 53–108) for the intervention 
group (MSU) and 153 min (IQR: 136–198, p=0.0011) in the 
control group (standard care). Alarm- to- therapy decision times 
were 35 min (IQR: 31–39) for the MSU group and 76 min (IQR: 
63–94, p<0.001) for the control group.14 These symptom onset- 
to- needle times were far superior to those found in all earlier 
registries or process quality improvement studies, including 
those with maximally streamlined in- hospital processes resulting 
in impressive door- to- needle times of even 20 min.23 37 Impor-
tantly, treatment quality and patient safety were not reduced 
when treatment occurred in an MSU.14
Some years later, in 2011, further MSUs hit the road. A 
pronounced time gain was also observed by a large, randomised 
study, the Pre- Hospital Acute Neurological Therapy and Opti-
mization of Medical Care in Stroke (PHANTOM- S) Study 
performed in Berlin, Germany, with median symptom onset- to- 
treatment times of 81 min (IQR: 56–129)38 and by observational 
studies in Houston, Texas, USA, with a mean symptom onset- to- 
treatment time of 98 min,39 and in Cleveland, Ohio, USA, with 
a median alarm- to- treatment time of 64 min (IQR: 58.3–72.5)40 
among other studies in various countries and healthcare envi-
ronments. The time gains in previous controlled studies are 
presented in figure 2.
The golden hour in stroke
Stroke physicians adopted the term ‘golden hour’ from trauma 
surgeons who first described the importance of the very early 
period after injury for the patient’s chances of survival. Indeed, 
analysis of an American registry showed that treatment of 
acute stroke within the golden hour is associated with a higher 
frequency of discharge to home, freedom from disability at 
discharge, and reduced rates of in- hospital complications and 
mortality.41
Before MSUs were implemented, only very few patients who 
had a stroke could be treated during the first hour: fewer than 
1%–2% were treated with thrombolysis during the golden hour 
in the National Institute of Neurological Disorders and Stroke 
rt- PA Stroke Study,42 the Safe Implementation of Treatments in 
Stroke Study43 or the Get With The Guidelines- Stroke registry.41 
A ceiling effect in conventional stroke management, associated 
with transport times and unavoidable intersections between the 
different groups of healthcare professionals, may explain why 
treatment during the golden hour is so rare. Until now, only the 
MSU approach has been able to break this ‘golden hour limit’ for 
the majority of patients, as was demonstrated by the results of a 
randomised trial (figure 3).14 Further studies have corroborated 
this dramatic increase in golden hour treatment with MSUs: 
the PHANTOM- S trial in Berlin, Germany, in which the rate of 
treatment within the first 60 min increased from 4.9% to 31%,44 
or the MSU project in Houston, Texas, in which 31% of the 
patients received thrombolysis during the golden hour.25
Treatment of haemorrhagic stroke
There is evidence that the ‘time is brain’ concept is valid for 
not only ischaemic stroke, but also haemorrhagic stroke. For 
example, haemorrhage enlargement occurs very early in the 
course of disease. Clarifying the haemorrhagic cause of stroke 
by using prehospital CT in MSUs allows appropriate triage 
decisions with regard to the transfer to specialised centres with 
neurosurgical services. One study found that on- scene infor-
mation about presence of the ‘spot sign’ in CT angiography, 
indicating ongoing haematoma enlargement,45 can be valuable 
in triage decision- making (figure 1C,D).16 Further, imaging in 
the field, apart from detection of subarachnoid haemorrhage 
allowed the detection of its vascular cause itself, a ruptured and 
still bleeding aneurysm, thereby enabling, after prenotification, 
to hand over the patient to the neurointerventional team directly 
in the angiography suite of a CSC.16
Finally, recommendations for blood pressure management 
differ depending on whether the stroke is of ischaemic or haem-
orrhagic origin.46 So far, only MSUs due to their imaging capa-
bilities allow differential blood pressure management already 
on- scene.11 The on- board POC laboratory can also provide 
relevant information about possible anticoagulant use, thereby 
allowing reversal of the effects not only of warfarin but also of 
novel oral anticoagulants such as idarucizumab for dabigatran 
Figure 4 In conventional stroke management, patients are transferred 
to the nearest stroke centre, which is usually a PSC. In case of presence of 
LVO, patients are, after thrombolysis, secondarily transferred to a CSC for 
intra- arterial therapy (‘drip- and- ship concept’) (A). In stroke management 
with a mobile stroke unit, LVO is diagnosed by vascular imaging on 
scene, enabling accurate triage decisions with regard to transport to the 
appropriate target hospital. Secondary interhospital transfers are no longer 
required (B).34 CSC, comprehensive stroke centre; CT- A, CT angiography; 
LVO, large- vessel occlusion; PSC, primary stroke centre; tPA, tissue 
plasminogen activator.
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or andexanet alpha for factor- Xa inhibitors.47 Indeed, in MSUs, 
feasibility of neutralising effects of dabigatran by idarucizumab 
has been shown in case of subdural haemorrhage.48 Apart from 
that, reversal of the effects of dabigatran has also been shown 
to be feasible for patients who had an ischaemic stroke, thereby 
enabling subsequent thrombolysis even for previously anticoag-
ulated patients.49
Role in triage of patients who had an acute stroke
Current stroke guidelines recommend that patients who had 
a stroke should be transported ‘to the closest available stroke 
centre, or, if no such facility is nearby, to the most appropriate 
institution that provides stroke care’.8 9 However, for most 
patients with LVO, the closest hospital is a primary stroke centre 
(PSC) that cannot offer thrombectomy. This subgroup of patients 
must be secondarily transferred to a CSC with the capability 
of performing IAT. This approach is called the ‘drip- and- ship’ 
concept, in case that a thrombolytic agent is administered in the 
receiving PSC before secondary transfer to a CSC.17 Importantly, 
it has been shown that such interhospital transfers cause detri-
mental delays ranging from 96 min to 111 min.50 Even when the 
distance between a PSC and a CSC is as small as 15 miles, inter-
hospital transfer times of 104 min have been reported.51
Apart from causing substantial delays before treatment, 
secondary transfers raise safety concerns due to the difficulty of 
adequate monitoring of patients during transfers and because of 
the repeated necessity of additional contrast- enhanced imaging 
in the target hospital, thereby increasing the risk of renal 
insufficiency.
In this context, MSUs can be viewed as a triage tool, because 
on- board vascular imaging detects LVO52 as precondition for 
correct triage decisions with regard to the appropriate target 
hospital (figure 4). This assumption was verified in a randomised 
trial involving 116 patients, which found that the diagnosis of 
LVO by vascular imaging in the MSU enables correct triage deci-
sions with regard to the appropriate target hospital (PSC vs CSC) 
with a sensitivity and specificity of 100%, thereby completely 
abolishing the need for secondary transfer.34
In this regard, Czap et al53 reported that implementation of CT 
angiography in the field also allows the reduction of in- hospital 
delays before IAT from 94.5 min (IQR: 69.8–117.3) to 41.0 min 
(IQR: 30.0–63.5; p<0.001), due to the option of earlier alerting 
of the endovascular team.
Open questions
Safety
Although the equipment in the MSU and the level of expertise 
of MSU personnel are similar to those found in hospitals,11 
concerns about the safety of MSU treatment have been raised.
Radiation emission by currently used radiation- shielded 
mobile scanners is within the range of that of fixed scanners in 
the hospital. A recent study confirmed that the 1- year occupa-
tional radiation exposures in MSUs using the Ceretom scanner 
(Neurologica, Boston, Massachusetts, USA) was 1.14 mSv, 
similar to the radiation exposure associated with in- hospital 
scanners and well below the dose limit of 5 mSv.54
Moreover, there are concerns that, in the prehospital arena, 
thrombolysis may accidentally be administered to patients who 
had stroke mimics more frequently than in hospitals because 
of the reduced time for observation of the disease course. This 
concern is, however, not specific to MSUs but applies to all 
interventions to improve process quality in stroke manage-
ment. In the previously reported controlled studies that varied 
in size of study population, inclusion criteria or dispatch algo-
rithms,14 38 40 55–58 a variable rate of mimics has been reported 
ranging between 9% and 40.9%; however, those rates were 
comparable with the respective control group at each study 
site.
So far, clinical studies have shown that the incidence of 
complications and the mortality rates among MSU- treated 
patients are not higher than those among patients treated in 
hospitals.11 14 24 25 38 59 In the previously reported controlled 
studies, rates of haemorrhagic complications among patients 
treated with intravenous tPA in an MSU ranged from 0% to 
3.5%, that were, again, similar to those reported for the respec-
tive control groups.14 38 40 55–58 In this regard, it has been shown 
that compared with later thrombolysis, earlier thrombolysis is 
associated not with higher but, conversely, with lower haemor-
rhagic complication rates.60 Despite this first evidence, safety 
Figure 5 World map of mobile stroke unit projects.
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endpoints should remain integral components of future MSU 
studies.
Effects on long-term outcomes
According to the ‘time is brain’ concept, the reduction of delays 
before treatment is generally considered to translate into better 
clinical outcomes,2 61 although the first trials were not designed 
or powered to determine differences in long- term outcomes.14 44
However, a meta- analysis of 11 previous trials involving 6065 
patients treated in MSUs found that these patients had a 1.46 
greater likelihood of better short- term outcomes than did patients 
given conventional care in a hospital (p=0.02), although mortality 
rates did not differ.62 In 2020, a large, non- randomised trial (Berlin 
Prehospital or Usual Delivery of Acute Stroke Care) performed in 
Berlin, Germany, found that 749 patients in an MSU group (MSU 
available) exhibited significantly better modified Rankin Scale (mRS) 
scores at day 90 than did 794 patients in a conventional treat-
ment group (MSU not available) (OR: 0.74, p<0.005).58 Finally, 
positive effects on long- term outcomes could be demonstrated 
in a randomised trial: the Benefits of Stroke Treatment Delivered 
by a Mobile Stroke Unit Compared to Standard Management by 
Emergency Medical Services Study was a prospective, multicentre, 
alternating- week, cluster- controlled trial performed at seven sites in 
the USA and involved 1047 tPA- eligible patients. The results showed 
that tPA treatment was administered significantly more frequently 
and more rapidly to patients in the MSU group: one- third of them 
were treated within the first, golden hour. Their primary outcome 
variable was mean mRS score at day 90. The results showed that the 
mean utility- weighted mRS scores were 0.726 for the MSU group 
and 0.657 for the group treated in a standard ambulance (difference, 
0.069; p=0.002). Thus, on average, for every 100 patients treated 
in an MSU rather than in a standard ambulance, 27 would have less 
disability, and 11 of the 27 would be disability- free.57
What is the optimal setting?
The efficiency of MSUs depends on the healthcare system, EMS 
configuration, legal requirements, market forces and population 
structure of a specific region.
Moreover, whether the urban, suburban or rural environ-
ment is the optimal setting remains uncertain. On the one 
hand, because the number of dispatches increases with popu-
lation density, MSUs would appear at first glance to be most 
beneficial in urban regions. A study performed in a very densely 
populated area (Manhattan, New York, USA) with a very high 
density of stroke centres found a time gain of 29.7 min; this time 
gain was similar to gains found in other, much less populated 
regions.56 This finding also suggests that a reduction in transport 
time is only one of several factors contributing to the time gain 
conferred by MSUs. On the other hand, remote rural regions are 
often strongly underserved with regard to stroke treatment, and 
transport delays are the main reason for very low thrombolysis 
rates in such regions.63 64 The medical value of MSUs, there-
fore, could be particularly high in such highly disadvantaged 
regions.34 65 66
Interestingly, as a means of increasing the action radius of 
MSUs, studies have evaluated a rendezvous concept, involving 
meeting the regular EMS en route. The MSU in Edmonton, 
Alberta, Canada, meets the regular ambulance at a predesignated 
site to reduce travel time, thereby extending the operating radius 
to as much as 250 km.66 Supporting such a rendezvous concept, 
a study performed in Houston, Texas, USA found no statistically 
significant difference in time to treatment between 169 patients 
transported by such a rendezvous pathway and 169 patients 
transported by the MSU alone (means±SD: 36.0±10 min vs 
37.0±10.0 min, p=0.65).67
Finally, specifically in remote regions, for example, in Australia 
or Norway, even aircraft equipped with equipment allowing the 
diagnosis and treatment of acute stroke could be a possible solu-
tion for a more equitable distribution of stroke care delivery. A 
concept and technical solutions for an Air- MSU, in which a heli-
copter or aeroplane is customised—analogously to MSUs—with 
a CT scanner, laboratory equipment and telemedicine connec-
tivity, have previously been proposed.68
Computational modelling of potential MSU missions can be 
supportive in consideration of the most efficient placement of 
future MSU programmes.69 70 For this aim, even smartphone 
applications have been developed (https:// gntem3. shinyapps. io/ 
ambmc/). Conditional probability modelling studies may also 
provide important information about the potential superiority 
of the MSU approach over other approaches, such as the drip- 
and- ship strategy, in a given region. So far, such estimates have 
shown that the benefits of MSUs depend mainly on a sufficient 
dispatch accuracy, the reached reduction of delay before throm-
bolysis and the process quality in stroke centres.71
Finally, for rational deployment of MSUs, one study involving 
195 treated patients addressed the best working time for MSUs. 
Morning (52.3%) and evening (35.8%) shifts accounted for 
88.1% of the MSU missions, whereas night missions accounted 
for only 11.9%.72 Very few MSUs operate 24/7 so far.73
Are MSUs too expensive?
In contrast to evidence supporting that the best chance of 
rescuing brain tissue from irreversible damage lies within the 
first hours and decreases rapidly thereafter, most resources are 
allocated to the later time after admission to the hospital. In this 
line, most MSU projects are still not adequately reimbursed but 
are funded by research grants, hospitals or charity organisations.
In contrast to previous concerns, the first estimation of the 
cost- effectiveness of an MSU showed a favourable benefit–cost 
ratio.65 74 Dietrich et al65 calculated a large number of scenarios 
based on data from the first controlled trial in Homburg, 
Germany.14 Benefit–cost ratios gradually increased as the number 
of MSU personnel has decreased (because of telemedicine) and 
the population density increased. Maximal benefit–cost ratios 
between 2.16 and 6.85 were found at an optimal operating 
distance between 26.73 and 40.32 miles, depending on the staff 
configuration. However, even in rural areas, benefit–cost ratios 
are higher than 1. This calculation did not even include addi-
tional beneficial effects of MSUs, such as correct triage decision- 
making with regard to LVO, prehospital differential blood 
pressure management or anticoagulant antagonisation.65
Table 1 Potential future diagnostic and therapeutic tools to be used 
in MSUs
Diagnostic Therapeutic
 ► Laboratory biomarkers of brain damage
 ► Doppler ultrasound
 ► CT scanners including evaluation of 
proximal cervical vessels
 ► Low field, small MRI
 ► Imaging analysis tools
 ► Sensor technologies (accelerometers, 
electroencephalography microwaves, 
near- infrared, radiofrequency, 
transcranial, volume impedance phase 
shift spectroscopy)
 ► Better thrombolytics
 ► Known and new neuroprotective 
agents
 ► Sonothrombolysis, drug- containing 
microbubbles
 ► Anticoagulant antagonists
 ► Hypothermia
 ► Surgical treatment of epidural 
haematoma
 ► Haemostatic treatment of 
haemorrhage
MSUs, mobile stroke units.
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An estimate by Gyrd- Hansen et al,74 based on data from the 
PHANTOM- S Study in Berlin, Germany,38 found that the annual 
net cost of MSU deployment (€963 954) was counterbalanced 
by a healthcare cost gain related to the avoidance of 80 cases 
of disability, equalling 29.7 quality- adjusted life- years (QALYs). 
This calculation produced an incremental cost- effectiveness 
ratio of €32 456 per QALY.
Finally, an economic evaluation based on data obtained from 
MSU missions in Melbourne, Australia, concluded that 16.90 
disability- adjusted life- years (DALYs) could be avoided with 
improvements in access to thrombolysis and that even 27.94 
DALYs could be avoided with earlier access to IAT enabled by 
deployment of MSUs. Use of the MSU was estimated to cost an 
additional $A30 982 per DALY avoided.75
There are several options for improving the cost- effectiveness of 
MSUs in the future: (1) reduction of personnel costs by using tele-
medicine consultations rather than on- board personnel24 26; (2) better 
integration of the MSU in routine EMS responses to maximise syner-
gistic effects; (3) reduction of hardware costs by using commercially 
available standard- ambulance solutions76 and by producing mobile 
scanners at higher volumes by more market competitors; (4) calcu-
lating the ideal number and locations of MSUs needed in a specific 
region to efficiently serve patients who had a stroke while keeping 
the number of simultaneous calls at a minimum; (5) using MSUs for 
traumatic brain injury,77 status epilepticus73 or subarachnoid haem-
orrhage16 77 78; and, finally, (6) increasing the utilisation rate of MSUs 
by improving stroke identification algorithms in the dispatch office. 
However, we can expect that, in the end, decisions about implemen-
tation of MSU will be based more on clinical evidence criteria than 
on explicit cost- effectiveness criteria.
CONCLUSION AND OUTLOOK
In conclusion, research into prehospital stroke treatment enabled 
by MSUs is a young field, which has been rapidly developing over 
recent years, with an expanding number of projects over the world 
(figure 5). Although MSUs are still experimental in some locations, 
their use is nearly routine in others. The proportion of MSU- treated 
patients worldwide is, however, still small. Further research is 
needed to define their best placement, their optimal integration into 
a given healthcare environment, and their long- term medical benefit 
and cost- effectiveness as a precondition for the sustainability of this 
concept.
There is much room for research in further improvement of the 
MSU concept, for example, the integration of novel diagnostic or 
therapeutic options that may become relevant in the future (table 1). 
For example, the use of tenecteplase, a thrombolytic drug that 
requires only a bolus rather than an infusion, could simplify on- scene 
treatment while offering similar or even greater effectiveness to 
alteplase. In addition, the long- standing topic of neuroprotection 
aimed at attenuating the detrimental cascade of molecular events in 
ischaemic neuronal injury is currently experiencing a revival in the 
era of prehospital stroke treatment options. The so far disappointing 
results of the hundreds of neuroprotection trials may be explained by 
the delivery of treatment too late and it is currently discussed that the 
most promising neuroprotective candidates should be re- evaluated 
when administered much earlier, for example, by use of MSUs.
Finally, we can expect that MSUs will strongly profit from 
future technological advances and from the improvement of 
connectivity promised by the 5G technology. In support of such 
research and of collaboration among healthcare professionals 
active in this field, the Prehospital Stroke Treatment Organiza-
tion has been founded as a non- profit international consortium 
open to everyone involved in this field ( www. prestomsu. org).
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